Noven Pharmaceuticals, Inc. today confirmed that Shire plc has launched Daytrana (methylphenidate transdermal system), the first and only transdermal medication approved to treat the symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in children aged six to twelve years, and that the product is now available in retail pharmacies. Shire, the market leader in ADHD, is the exclusive, global licensee of Daytrana, which was developed and is manufactured by Noven.
Finanzen.net
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Theradiag Snags CE Mark for Biotherapy Monitoring Analyzer
The i-Track10 can be integrated into laboratory automation systems and features random access analysis and continuous loading capabilities.
Petition Urges FDA, DEA to Classify Tramadol as a Schedule II Controlled Substance
The DEA classified tramadol as a Schedule IV controlled substance in 2014.
FDAnews Device Daily Bulletin
NOVEN CONFIRMS AVAILABILITY OF DAYTRANA METHYLPHENIDATE TRANSDERMAL SYSTEM
July 3, 2006
